Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime–tazobactam sodium (3:1) in moderate to severe acute bacterial infections
CTR20140296Phase 4Active
- Sponsor
- Kangzhi Pharmaceutical
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + tazobactam in There is no single canonical disease name for "acute bacterial infection" as it refers to a broad category of diseases rather than a specific condition., sponsored by Kangzhi Pharmaceutical. Started Jun 2014; status: active.
02
Drugs
ceftazidime + tazobactam
03
Conditions
There is no single canonical disease name for "acute bacterial infection" as it refers to a broad category of diseases rather than a specific condition.
Beyond the preview
Go deeper on CTR20140296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140296.